Cardiovascular Medicine and Research II.
Dr. Tokodi, Márton, PhD
zieufc
Heart and Vascular Center, Semmelweis University, Budapest, Hungary
+36304652356
tokmarton@gmail.com
Machine Learning-Based Mortality Prediction in Patients Undergoing CRT Implantation Using the SEMMELWEIS-CRT Score: Validation in the European CRT Survey I Dataset
Márton Tokodi1, Annamária Kosztin1, Attila Kovács1, László Gellér1, Walter Richard Schwertner1, Boglárka Veres1, Anett Behon1, Christiane Lober2, Nigussie Bogale3, Cecilia Linde4, Camilla Normand5, Kenneth Dickstein5, Béla Merkely1
1: Heart and Vascular Center, Semmelweis University, Budapest, Hungary
2: Institut für Herzinfarktforschung, Ludwigshafen, Germany
3: Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
4: Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
5: Cardiology Division, Stavanger University Hospital, Stavanger, Norway
Szóbeli
Cardiovascular Medicine and Research II.
English
Cardiovascular Medicine and Research
Introduction: Cardiac resynchronization therapy (CRT) plays a crucial role in the management of heart failure patients. Nevertheless, significant variation in clinical outcomes can still be observed among patients undergoing CRT implantation, which has prompted the development of various machine learning (ML)-based risk stratification tools in this patient population. One such tool is the publicly available SEMMELWEIS-CRT score, which exhibited impressive performance during internal validation but has not been validated externally yet.
Aims: We aimed to externally validate the SEMMELWEIS-CRT score for predicting 1-year all-cause mortality in the European CRT Survey I dataset – a large multi-center cohort of patients undergoing CRT implantation.
Methods: The SEMMELWEIS-CRT score is an ML-based risk stratification tool designed to predict all-cause mortality in patients undergoing CRT implantation. It is a random forest classifier trained in a large retrospective single-center dataset of CRT candidates (n=1,510), taking 33 clinical features as input. In the present study, we applied it to the data of 1,367 patients from the European CRT Survey I dataset.
Results: During the 1-year follow-up period, 122 (9%) of the 1,367 patients died. The SEMMELWEIS-CRT score predicted 1-year mortality with an area under the receiver operating characteristic curve (AUC) of 0.729 [0.682 – 0.776], which concurred with the performance measured during internal validation (AUC: 0.768 [0.674 – 0.861], p=0.466). Moreover, the SEMMELWEIS-CRT score outperformed multiple conventional statistics-based risk scores, including the VALID-CRT (AUC: 0.658 [0.607 – 0.709], p=0.022), the EAARN (AUC: 0.665 [0.619 – 0.711], p=0.016), and the ScREEN scores (AUC: 0.645 [0.600 – 0.691], p=0.003).
Conclusions: In the European CRT Survey I dataset, the SEMMELWEIS-CRT score predicted 1-year all-cause mortality with good discriminatory power, confirming its generalizability and demonstrating its potential clinical utility as an ML-based risk stratification tool in CRT candidates.
Funding: Project no. RRF-2.3.1-21-2022-00004 (MILAB) has been implemented with the support provided by the European Union. Márton Tokodi was supported by the New National Excellence Program (ÚNKP-23-4-II-SE-39) of the Ministry of Culture and Innovation in Hungary from the National Research, Development, and Innovation Fund.
Semmelweis University
N/A
I do not give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
szóbeli
nem rendelkezett róla
4173
14:45
14:55